NASDAQ:ONCE - Spark Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$87.75 +4.87 (+5.88 %)
(As of 06/20/2018 10:49 AM ET)
Previous Close$84.44
Today's Range$84.41 - $87.85
52-Week Range$41.06 - $91.75
Volume8,920 shs
Average Volume462,962 shs
Market Capitalization$2.87 billion
P/E Ratio-11.13
Dividend YieldN/A
Beta2.53
Spark Therapeutics logoSpark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of CLN2 disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Receive ONCE News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONCE
CUSIPN/A
Phone888-772-7560

Debt

Debt-to-Equity RatioN/A
Current Ratio11.37
Quick Ratio11.27

Price-To-Earnings

Trailing P/E Ratio-11.13
Forward P/E Ratio-25.36
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.07 million
Price / Sales271.83
Cash FlowN/A
Price / CashN/A
Book Value$13.88 per share
Price / Book6.32

Profitability

EPS (Most Recent Fiscal Year)($7.63)
Net Income$-253,480,000.00
Net Margins-935.38%
Return on Equity-51.76%
Return on Assets-42.28%

Miscellaneous

Employees315
Outstanding Shares37,390,000

Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics Inc (NASDAQ:ONCE) posted its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.45) by $0.80. The biotechnology company had revenue of $15.68 million for the quarter, compared to analysts' expectations of $51.55 million. Spark Therapeutics had a negative net margin of 935.38% and a negative return on equity of 51.76%. Spark Therapeutics's revenue was up 1134.6% on a year-over-year basis. During the same period last year, the firm posted ($1.70) EPS. View Spark Therapeutics' Earnings History.

What price target have analysts set for ONCE?

21 analysts have issued 1-year price objectives for Spark Therapeutics' shares. Their forecasts range from $40.00 to $113.00. On average, they expect Spark Therapeutics' stock price to reach $76.10 in the next twelve months. View Analyst Ratings for Spark Therapeutics.

What are Wall Street analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:
  • 1. Raymond James analysts commented, "We are maintaining our Outperform rating for Spark. Hemophilia (WFH) 2018 World Congress, the company, along with its partner, Pfizer, provided an update on the ongoing Phase I/II study evaluating SPK-9001 for hemophilia B (Hem B). In addition, Spark’s competitor, BioMarin, provided an update on the ongoing Phase I/II trial of valoctocogene roxaparvovec (or BMN 270) in severe hemophilia A (Hem A)." (5/23/2018)
  • 2. Mizuho analysts commented, "We expect the update to be an important catalyst given the large market opportunity in this indication. We expect to see data from three-dose cohorts and a longer follow-up time since the last update at the Hematology (ASH) in December 2017. Management is also advancing preparations for a phase 3 trial in parallel." (5/8/2018)
  • 3. Cantor Fitzgerald analysts commented, "Updates to our Model. We are increasing our PT to $103/share from $100, based on the adjustment to our estimate of 2018 YE net cash. This increase is driven by a year-end cash increase from $549 million to $659 million ($18/ share), which accounts for the $110 million increase (a $3/share increase)." (4/30/2018)

Who are some of Spark Therapeutics' key competitors?

Who are Spark Therapeutics' key executives?

Spark Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey D. Marrazzo M.B.A., M.P.A., Co-Founder, CEO & Director (Age 39)
  • Dr. Katherine A. High, Co-Founder, Pres and Chief Scientific Officer (Age 66)
  • Mr. Stephen W. Webster, Chief Financial Officer (Age 57)
  • Mr. John Furey, Chief Operating Officer (Age 53)
  • Mr. Daniel R. Faga, Chief Bus. Officer (Age 38)

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Has Spark Therapeutics been receiving favorable news coverage?

News articles about ONCE stock have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Spark Therapeutics earned a media sentiment score of 0.12 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.12 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Spark Therapeutics' major shareholders?

Spark Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.08%), Federated Investors Inc. PA (4.02%), Rock Springs Capital Management LP (1.67%), Sofinnova Ventures Inc (1.29%), OppenheimerFunds Inc. (1.14%) and Rockefeller Capital Management L.P. (0.96%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics.

Which major investors are selling Spark Therapeutics stock?

ONCE stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Wells Fargo & Company MN, Eventide Asset Management LLC, Element Capital Management LLC, SG Americas Securities LLC, Guggenheim Capital LLC, Jane Street Group LLC and BlackRock Inc.. Company insiders that have sold Spark Therapeutics company stock in the last year include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Insider Buying and Selling for Spark Therapeutics.

Which major investors are buying Spark Therapeutics stock?

ONCE stock was acquired by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Rockefeller Capital Management L.P., PointState Capital LP, Pinnacle Associates Ltd., OppenheimerFunds Inc., UBS Group AG, Point72 Asset Management L.P. and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Spark Therapeutics.

How do I buy shares of Spark Therapeutics?

Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spark Therapeutics' stock price today?

One share of ONCE stock can currently be purchased for approximately $87.37.

How big of a company is Spark Therapeutics?

Spark Therapeutics has a market capitalization of $2.87 billion and generates $12.07 million in revenue each year. The biotechnology company earns $-253,480,000.00 in net income (profit) each year or ($7.63) on an earnings per share basis. Spark Therapeutics employs 315 workers across the globe.

How can I contact Spark Therapeutics?

Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]


MarketBeat Community Rating for Spark Therapeutics (ONCE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  359 (Vote Outperform)
Underperform Votes:  280 (Vote Underperform)
Total Votes:  639
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.